Search Result

Results for "

humanized mouse model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA synthetase (1) Apoptosis (1) c-Myc (1) CCR (1) Complement System (1) CTLA-4 (1) CXCR (1) Dihydroorotate Dehydrogenase (1) Discoidin Domain Receptor (1) Free Fatty Acid Receptor (1) HBV (1) HIV (1) Integrin (1) Interleukin Related (5) LILRB (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) Microtubule/Tubulin (1) Myosin (1) Na+/K+ ATPase (1) NF-κB (2) Orexin Receptor (OX Receptor) (1) Orphan GPCR (1) Parasite (5) PD-1/PD-L1 (4) PROTACs (1) RIP kinase (1) STAT (1) TGF-beta/Smad (1) TNF Receptor (2) Transmembrane Glycoprotein (3)
By Research Areas:	Cancer (19) Infection (7) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Acetyl-CoA synthetase (1)

Apoptosis (1)

c-Myc (1)

CCR (1)

Complement System (1)

CTLA-4 (1)

CXCR (1)

Dihydroorotate Dehydrogenase (1)

Discoidin Domain Receptor (1)

Free Fatty Acid Receptor (1)

HBV (1)

HIV (1)

Integrin (1)

Interleukin Related (5)

LILRB (1)

Mas-related G-protein-coupled Receptor (MRGPR) (1)

Microtubule/Tubulin (1)

Myosin (1)

Na+/K+ ATPase (1)

NF-κB (2)

Orexin Receptor (OX Receptor) (1)

Orphan GPCR (1)

Parasite (5)

PD-1/PD-L1 (4)

PROTACs (1)

RIP kinase (1)

STAT (1)

TGF-beta/Smad (1)

TNF Receptor (2)

Transmembrane Glycoprotein (3)

By Research Areas:

Cancer (19)

Infection (7)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150233

Cys-McMMAF	Microtubule/Tubulin	Cancer
Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .

HY-P99056

Utomilumab PF 05082566	TNF Receptor	Inflammation/Immunology Cancer
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 ⁺ non-Hodgkin lymphomas .

HY-P99728

Melredableukin alfa RG7835; RO7049665	Interleukin Related	Metabolic Disease Inflammation/Immunology
Melredableukin alfa (RG7835) is a bivalent conjugate composed of a human IL-2 mutant (T3A, N88D, C125A) and human IgG1. Melredableukin alfa exhibits enhanced Treg cell selectivity in cynomolgus monkey and humanized mouse models. Melredableukin alfa can be used in research related to ulcerative colitis and autoimmune hepatitis .

HY-P99697

Leronlimab PRO 140	CCR HIV	Infection Cancer
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .

HY-P991363

AX-202	Myosin STAT	Inflammation/Immunology
AX-202 is a humanized IgG4 monoclonal antibody targeting S100A4. AX-202 neutralizes the activity of S100A4. AX-202 effectively reverses established fibrosis and reduces inflammation and fibrosis-related biomarkers in a mouse model of skin fibrosis. AX-202 is applicable for the research of fibrotic and inflammatory diseases .

HY-P990993

Emugrobart GYM-329, RG6237, RG-70240	TGF-beta/Smad	Inflammation/Immunology
Emugrobart (GYM-329, RG6237, RG-70240) is a humanized IgG1κ antibody targeting myostatin (Myostatin; GDF8). Emugrobart binds to pro-myostatin and latent myostatin, blocking their cleavage into mature myostatin; it also has a clearance function, which transports bound myostatin for degradation and allows for cyclic reuse. Emugrobart enhances muscle strength in mouse models of muscle atrophy and increases muscle mass in cynomolgus monkeys. Emugrobart can be used in research on spinal muscular atrophy and facioscapulohumeral muscular dystrophy .

HY-P991598

MOR-106 MOR12743; MOR03207	Interleukin Related NF-κB	Inflammation/Immunology
MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC₅₀ = 59 pM for human IL-17C, IC₅₀ = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .

HY-142221

ARB-272572	PD-1/PD-L1	Cancer
ARB-272572 is an oral effective small molecule PD-L1 inhibitor, with an IC₅₀ value of 400 pM. ARB-272572 has research significance in tumors and chronic viral infections .

HY-P99249

Vonlerolizumab Pogalizumab; MOXR 0916	Orexin Receptor (OX Receptor)	Cancer
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models .

HY-P990025

Empasiprubart ARGX-117	Complement System	Inflammation/Immunology
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .

HY-P99395

Talacotuzumab 1 Publications Verification JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-175370

PROTAC RIPK1 Degrader-1	PROTACs RIP kinase	Cancer
PROTAC RIPK1 Degrader-1 is a selective RIPK1 PROTAC degrader. PROTAC RIPK1 Degrader-1 degrades RIPK1 in multiple cancer cell lines (e.g., A375, B16F10 cells). PROTAC RIPK1 Degrader-1 enhances the anti-cancer effect of radiotherapy in syngeneic and humanized mouse models. PROTAC RIPK1 Degrader-1 can be used to study cancers such as melanoma. (Pink: RIPK1-ligand-2: HY-175371, Blue: (S,R,S)-AHPC-Me: HY-112078, Pink + Black: RIPK1 ligand-Linker Conjugate-1: HY-175374, Black: Bispiperidin-piperazin-acetater: HY-175373) .

HY-P991674

Brelovitug BJT-778	HBV	Infection Inflammation/Immunology
Brelovitug (BJT-778) is a humanized IgG1 neutralizing monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Brelovitug binds with high affinity to HBsAg purified from HBV serotypes ad and ay, with K_d values of 0.22 nM and 0.39 nM, respectively. Brelovitug binds with high affinity to HBsAg of HBV genotypes A, B, C and D, with IC₅₀ values of 0.07, 0.02, 0.02 and 0.07 nM, respectively. Brelovitug can be used in research related to chronic hepatitis B and chronic hepatitis D .

HY-170780

DSM1465	Parasite Dihydroorotate Dehydrogenase	Infection
DSM1465 (Compound 82) is a potent, selective inhibitor of P. falciparum dihydroorotate dehydrogenase (PfDHODH) with an IC₅₀ value of 15 nM, inhibits P. falciparum 3D7 (Pf3D7) parasites with an EC₅₀ value of 1.4 nM. DSM1465 shows potent in vivo activity in the humanized P. falciparum mouse model .

HY-P991646

ING-1 heMab	Transmembrane Glycoprotein	Cancer
ING-1 (heMab) is a high-affinity humanized monoclonal antibody against epithelial cell adhesion molecule (Ep-CAM). ING-1 is a transmembrane glycoprotein mediating Ca ²⁺. ING-1 binds to Ep-CAM on tumor cells and exhibits potent in vitro activity, targeting and inhibiting tumor growth and metastasis in mouse cancer models. ING-1 is useful in the research of breast, colorectal, and lung cancers, among other cancers .

HY-111141

AM-3189	Free Fatty Acid Receptor	Metabolic Disease
AM-3189 is an orally active and selective GPR40 agonist with EC₅₀ values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes .

HY-P991432

VTX-0811	TNF Receptor NF-κB c-Myc	Cancer
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma .

HY-163837

PD-1/PD-L1-IN-48	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-48 (compound HD10) is a potent inhibitor of PD-1/PD-L1 interaction, with an IC₅₀ of 3.1 nM. PD-1/PD-L1-IN-48 plays an important role in cancer research .

HY-P991587

SAR-446523	Orphan GPCR	Cancer
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .

HY-P991639

BIW-8962	Apoptosis	Cancer
BIW-8962 is a humanized anti-ganglioside GM2 antibody. BIW-8962 exhibits ADCC/CDC activity against multiple myeloma cells. BIW-8962 demonstrates potent anti-tumor activity in mouse xenograft models. BIW-8962 is indicated for research in myeloma and other cancers .

HY-172953

Insecticidal agent 24	Parasite	Infection
Insecticidal agent 24 is an orally active pyridylspiroindoline frontrunner. Insecticidal agent 24 has antiplasmodial activity (Pf NF54 IC₅₀: 0.08 μM). Insecticidal agent 24 inhibits hERG activity (IC₅₀: 6.5 μM). Insecticidal agent 24 reduces parasitemia in a humanized immunodeficient NSG mouse Plasmodium falciparum infection model .

HY-155740

PD-1/PD-L1-IN-32	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC₅₀=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability .

HY-111817A

(Rac)-ACT-451840	Parasite	Infection
(Rac)-ACT-451840 is an isomer of ACT-451840 that exhibits significant antimalarial effects. (Rac)-ACT-451840 exhibits significant antimalarial activity against P. berghei-infected mice at a dose of 20 mg/kg (ED90=13 mg/kg), and has an inhibitory effect at a dose of 300 mg/kg. The ED90 of (Rac)-ACT-451840 in the P. falciparum humanized immunodeficient mouse model is 3.7 mg/kg. (Rac)-ACT-451840 is similar to artemisinin, with a rapid onset of action but requires repeated high doses.

HY-180802

BCFTP	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease
BCFTP is a potent, orally active and selective human Mas-related G protein-coupled receptor X1 (MrgprX1)-positive allosteric modulator. BCFTP selectively potentiates MrgprX1 signaling in HEK293 cells. BCFTP alleviates specific neuropathic pain-related behaviors in a humanized MrgprX1 mouse model of chronic constrictive injury (CCI) in a MrgprX1-dependent manner. BCFTP synergistically enhances psychoactive substances analgesia in CCI MrgprX1 mice. BCFTP can be used for neuropathic pain research .

HY-182685

MMV693183	Acetyl-CoA synthetase Parasite	Infection
MMV693183 is an orally active inhibitor of Plasmodium falciparum acetyl-CoA synthetase (AcAS), with an IC₅₀ of 300 nM against Plasmodium falciparum. MMV693183 exhibits potent inhibitory activity against clinical isolates of malaria parasites, including Artemisinin (HY-B0094)-resistant strains. MMV693183 is metabolized in vivo into the active antimetabolite CoA-MMV693183, which exerts effects of killing asexual blood-stage parasites and blocking transmission to Anopheles mosquitoes by binding to and inhibiting the function of acetyl-CoA synthetase, thereby reducing the levels of acetyl-CoA and 4'-phosphopantetheine. In humanized mouse models, MMV693183 shows favorable in vivo efficacy, drug-like properties, and no significant cytotoxicity or off-target activity against human cells. MMV693183 is widely used in malaria-related research as a parasiticide and metabolic disruptor .

HY-P992436

PAS-003	Integrin	Neurological Disease
PAS-003 is a humanized monoclonal antibody targerting α5β1 integrin. PAS-003 modulates immune cell migration, immune cell adhesion, improves behavior, and improves survival in ALS mouse models. PAS-003 can be used for the research of amyotrophic lateral sclerosis .

HY-P992066

Anti-Mouse DDR2 Antibody (DAB0065)	Discoidin Domain Receptor	Inflammation/Immunology
Anti-Mouse DDR2 Antibody (DAB0065) is a mAb that specifically targets mouse discoidin domain receptor DDR2 without cross-reacting with DDR1. Anti-Mouse DDR2 Antibody (DAB0065) binds to the extracellular domain of native mouse DDR2, induces endocytosis and lysosomal degradation of DDR2, and this process is independent of collagen binding. Anti-Mouse DDR2 Antibody (DAB0065) exhibits significant therapeutic effects in both the unilateral ureteral obstruction (UUO) mouse model of renal fibrosis and the bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, effectively downregulating the mRNA expression of type I collagen Col1a1 and fibronectin Fn1. Anti-Mouse DDR2 Antibody (DAB0065) can be humanized and has the potential to be developed as a targeted agent for diseases such as idiopathic pulmonary fibrosis and renal fibrosis .

HY-P991960

JS007	CTLA-4 Interleukin Related	Cancer
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a K_d of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.

HY-181821

MMV1581361	Parasite Na+/K+ ATPase	Infection
MMV1581361 is a PfATP4 inhibitor and an orally active, transmission-blocking agent with nanomolar activity against Plasmodium falciparum blood-stage isolates. MMV1581361 disrupts sodium ion (Na ⁺) homeostasis in Plasmodium falciparum. MMV1581361 inhibits male gamete exflagellation, reduces oocyst intensity, and blocks transmission of Plasmodium falciparum. MMV1581361 demonstrates efficacy in the humanized Plasmodium falciparum NOD scid IL2Rγ ^null mouse model. MMV1581361 can be used for the research of malaria .

HY-P992352

ES005
ES005 is an anti-tumor compound and LAG3 inhibitor. ES005 blocks the interactions of LAG3 with MHC-II, LSECtin and FGL1, thereby effectively reversing the LAG3-mediated inhibition of T cell activation and NFAT reporter gene expression. ES005 exhibits significant tumor growth inhibitory effects in syngeneic mouse breast tumor models using humanized LAG3 knock-in mice. ES005 can be used for breast tumor-related research .

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer .

HY-P992388

IO-108	LILRB	Cancer
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a K_D value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .

HY-P992382

IC 100	Interleukin Related	Neurological Disease Inflammation/Immunology
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003 .

HY-185565

PD-1/PD-L1-IN-63	PD-1/PD-L1 CXCR	Cancer
PD-1/PD-L1-IN-63 is an orally active PD-1/PD-L1 inhibitor with an IC₅₀ of 9.1 nM. PD-1/PD-L1-IN-63 blocks the PD-1/PD-L1 interaction, induces cancer cell death and inhibits tumor growth. PD-1/PD-L1-IN-63 can be used in the research of melanoma .

HY-P992005

DS-1055a	Transmembrane Glycoprotein	Cancer
DS-1055a is an anti-human GARP antibody. DS-1055a effectively depletes GARP-positive regulatory T cells in the tumor microenvironment, and activates effector T cells. DS-1055a exhibits antitumor activity and can be used for the research of cancer, such as colon cancer .

Cat. No.	Product Name	Target	Research Area	Image